Ursula Keber
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ursula Keber has a total of 139 co-authors. Here are the top co-authors by number of shared publications:
Axel Pagenstecher
Institute of Neuropathology, Philipps-University Marburg and University Hospital Marburg, Marburg, Germany
3 shared publications- Carsten Denkert
Institut für Pathologie, Philipps Universität Marburg und Universitätsklinikum Marburg (UKGM), Marburg, Germany
2 shared publications - Abbas Agaimy
Institute of Pathology, Erlangen University Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany
1 shared publication - Akira Hattesohl
Institute of Pathology, Philipps-University Marburg and University Hospital Marburg (UKGM), Marburg, Germany
1 shared publication - Albert Grass
Institute of Pathology, Philipps-University Marburg and University Hospital Marburg (UKGM), Marburg, Germany
1 shared publication Alfredo Marinelli
Department of Medicina Clinica e Chirurgia, University Federico II, Naples, Italy
1 shared publication
Latest Publications
- Open Access
- 25 September 2026
- Published by Springer Nature in Pituitary
- Vol. 29 (5) , 160
Staining collagen fibers in pituitary lesions substantially improves the certainty of intraoperative frozen section diagnosis
Purpose: Transsphenoidal surgery is the first-line treatment for most pituitary adenomas (PA), also known as pituitary neuroendocrine tumors (PitNET), and a precise intraoperative histopathological evaluation of tissue samples is essential to optimize tumor resection and clinical outcome. However, it still remains a challenge for pathologists to distinguish between PA and pituitary gland. In this study, we evaluated the effect of an additional Cason collagen fiber stain on the accuracy of intraoperative histopathological diagnostics of PAs by visualizing either physiologically retained or pathologically lost lobulation. Methods: A total of 252 cases were included in this study. In the control group ( n = 93) cytological smear preparations and H&E-stained frozen sections were evaluated. In the experimental group ( n = 159), both H&E- and Cason-stained frozen sections as well as smear preparations were examined. The concordance rate of the intraoperative diagnoses with the final diagnoses made on the paraffin material was determined. Results: When compared with the HE only group, the HE+Cason approach markedly increased the diagnostic accuracy from 87% to 98% ( p < 0.001), sensitivity from 90% to 98% ( p < 0.05) and specificity from 40% to 100% ( p = 0.06), whereas the rate of inconclusive cases was significantly reduced from 11% to 0% ( p < 0.001). Conclusion: This study introduces the Cason stain on frozen sections as a rapid, simple and inexpensive diagnostic tool essentially improving certainty in intraoperative histopathological diagnostics of PAs, thus facilitating surgical decision-making and optimizing clinical outcomes.
- 25 September 2026
- Published by Springer Nature in Pituitary
- Vol. 29 (5) , 160
Open AccessStaining collagen fibers in pituitary lesions substantially improves the certainty of intraoperative frozen section diagnosis
Purpose: Transsphenoidal surgery is the first-line treatment for most pituitary adenomas (PA), also known as pituitary neuroendocrine tumors (PitNET), and a precise intraoperative histopathological evaluation of tissue samples is essential to optimize tumor resection and clinical outcome. However, it still remains a challenge for pathologists to distinguish between PA and pituitary gland. In this study, we evaluated the effect of an additional Cason collagen fiber stain on the accuracy of intraoperative histopathological diagnostics of PAs by visualizing either physiologically retained or pathologically lost lobulation. Methods: A total of 252 cases were included in this study. In the control group ( n = 93) cytological smear preparations and H&E-stained frozen sections were evaluated. In the experimental group ( n = 159), both H&E- and Cason-stained frozen sections as well as smear preparations were examined. The concordance rate of the intraoperative diagnoses with the final diagnoses made on the paraffin material was determined. Results: When compared with the HE only group, the HE+Cason approach markedly increased the diagnostic accuracy from 87% to 98% ( p < 0.001), sensitivity from 90% to 98% ( p < 0.05) and specificity from 40% to 100% ( p = 0.06), whereas the rate of inconclusive cases was significantly reduced from 11% to 0% ( p < 0.001). Conclusion: This study introduces the Cason stain on frozen sections as a rapid, simple and inexpensive diagnostic tool essentially improving certainty in intraoperative histopathological diagnostics of PAs, thus facilitating surgical decision-making and optimizing clinical outcomes.
- Open Access
- 3 April 2026
- Published by Elsevier in Cancer Genetics
- Vol. 304-305, 103-113
Optimized precision oncology through implementation of a comprehensive molecular analysis pipeline – relevance for additional therapeutic options
- 3 April 2026
- Published by Elsevier in Cancer Genetics
- Vol. 304-305, 103-113
Open AccessOptimized precision oncology through implementation of a comprehensive molecular analysis pipeline – relevance for additional therapeutic options
- Open Access
- 20 November 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-13
Brain-to-gut trafficking of alpha-synuclein by CD11c+ cells in a mouse model of Parkinson’s disease
Inflammation in the brain and gut is a critical component of several neurological diseases, such as Parkinson’s disease (PD). One trigger of the immune system in PD is aggregation of the pre-synaptic protein, α-synuclein (αSyn). Understanding the mechanism of propagation of αSyn aggregates is essential to developing disease-modifying therapeutics. Using a brain-first mouse model of PD, we demonstrate αSyn trafficking from the brain to the ileum of male mice. Immunohistochemistry revealed that the ileal αSyn aggregations are contained within CD11c+ cells. Using single-cell RNA sequencing, we demonstrate that ileal CD11c+ cells are microglia-like and the same subtype of cells is activated in the brain and ileum of PD mice. Moreover, by utilizing mice expressing the photo-convertible protein, Dendra2, we show that CD11c+ cells traffic from the brain to the ileum. Together these data provide a mechanism of αSyn trafficking between the brain and gut.
- 20 November 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-13
Open AccessBrain-to-gut trafficking of alpha-synuclein by CD11c+ cells in a mouse model of Parkinson’s disease
Inflammation in the brain and gut is a critical component of several neurological diseases, such as Parkinson’s disease (PD). One trigger of the immune system in PD is aggregation of the pre-synaptic protein, α-synuclein (αSyn). Understanding the mechanism of propagation of αSyn aggregates is essential to developing disease-modifying therapeutics. Using a brain-first mouse model of PD, we demonstrate αSyn trafficking from the brain to the ileum of male mice. Immunohistochemistry revealed that the ileal αSyn aggregations are contained within CD11c+ cells. Using single-cell RNA sequencing, we demonstrate that ileal CD11c+ cells are microglia-like and the same subtype of cells is activated in the brain and ileum of PD mice. Moreover, by utilizing mice expressing the photo-convertible protein, Dendra2, we show that CD11c+ cells traffic from the brain to the ileum. Together these data provide a mechanism of αSyn trafficking between the brain and gut.
- Top Cited PapersOpen Access
- 28 November 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-14
DNA methylation-based classification of sinonasal tumors
The diagnosis of sinonasal tumors is challenging due to a heterogeneous spectrum of various differential diagnoses as well as poorly defined, disputed entities such as sinonasal undifferentiated carcinomas (SNUCs). In this study, we apply a machine learning algorithm based on DNA methylation patterns to classify sinonasal tumors with clinical-grade reliability. We further show that sinonasal tumors with SNUC morphology are not as undifferentiated as their current terminology suggests but rather reassigned to four distinct molecular classes defined by epigenetic, mutational and proteomic profiles. This includes two classes with neuroendocrine differentiation, characterized by IDH2 or SMARCA4/ARID1A mutations with an overall favorable clinical course, one class composed of highly aggressive SMARCB1-deficient carcinomas and another class with tumors that represent potentially previously misclassified adenoid cystic carcinomas. Our findings can aid in improving the diagnostic classification of sinonasal tumors and could help to change the current perception of SNUCs.
- 28 November 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-14
Top Cited PapersOpen AccessDNA methylation-based classification of sinonasal tumors
The diagnosis of sinonasal tumors is challenging due to a heterogeneous spectrum of various differential diagnoses as well as poorly defined, disputed entities such as sinonasal undifferentiated carcinomas (SNUCs). In this study, we apply a machine learning algorithm based on DNA methylation patterns to classify sinonasal tumors with clinical-grade reliability. We further show that sinonasal tumors with SNUC morphology are not as undifferentiated as their current terminology suggests but rather reassigned to four distinct molecular classes defined by epigenetic, mutational and proteomic profiles. This includes two classes with neuroendocrine differentiation, characterized by IDH2 or SMARCA4/ARID1A mutations with an overall favorable clinical course, one class composed of highly aggressive SMARCB1-deficient carcinomas and another class with tumors that represent potentially previously misclassified adenoid cystic carcinomas. Our findings can aid in improving the diagnostic classification of sinonasal tumors and could help to change the current perception of SNUCs.
- Open Access
- 25 May 2022
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 198 (10) , 892-906
Monocentric evaluation of Ki-67 labeling index in combination with a modified RPA score as a prognostic factor for survival in IDH-wildtype glioblastoma patients treated with radiochemotherapy
Purpose: The prognosis for glioblastoma patients remains dismal despite intensive research on better treatment options. Molecular and immunohistochemical markers are increasingly being investigated as understanding of their role in disease progression grows. O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation has been shown to have prognostic and therapeutic relevance for glioblastoma patients. Other markers implicated in tumor formation and/or malignancy are p53, Alpha thalassemia/mental retardation syndrome X-linked (ATRX), Epidermal Growth Factor Receptor splice variant III (EGFRvIII), and Ki-67, with loss of nuclear ATRX expression and lower Ki-67 index being associated with prolonged survival. For p53 and EGFRvIII the data are contradictory. Our aim was to investigate the markers mentioned above regarding progression-free (PFS) and overall survival (OS) to evaluate their viability as independent prognostic markers for our patient collective. Methods: In this retrospective study, we collected data on patients undergoing radiotherapy due to isocitrate dehydrogenase (IDH) wildtype glioblastoma at a single university hospital between 2014 and 2020. Results: Our findings confirm Ki-67 labeling index ≤ 20% as an independent prognostic factor for prolonged PFS as well as MGMT promoter methylation for both prolonged PFS and OS, in consideration of age and Eastern Cooperative Oncology Group (ECOG) status, chemotherapy treatment, and total radiation dose for PFS as well as additionally sex, resection status, and receipt of treatment for progression or recurrence for OS. Additionally, Ki-67 labeling index ≤ 20% showed a significant correlation with prolonged OS in univariate analysis. Modification of the recursive partitioning analysis (RPA) score to include Ki-67 labeling index resulted in a classification with the possible ability to distinguish long-term-survivors from patients with unfavorable prognosis. Conclusion: MGMT promoter methylation and Ki-67 labeling index were independent predictors of survival in our collective. We see further studies pooling patient collectives to reach larger patient numbers concerning Ki-67 labeling index as being warranted.
- 25 May 2022
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 198 (10) , 892-906
Open AccessMonocentric evaluation of Ki-67 labeling index in combination with a modified RPA score as a prognostic factor for survival in IDH-wildtype glioblastoma patients treated with radiochemotherapy
Purpose: The prognosis for glioblastoma patients remains dismal despite intensive research on better treatment options. Molecular and immunohistochemical markers are increasingly being investigated as understanding of their role in disease progression grows. O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation has been shown to have prognostic and therapeutic relevance for glioblastoma patients. Other markers implicated in tumor formation and/or malignancy are p53, Alpha thalassemia/mental retardation syndrome X-linked (ATRX), Epidermal Growth Factor Receptor splice variant III (EGFRvIII), and Ki-67, with loss of nuclear ATRX expression and lower Ki-67 index being associated with prolonged survival. For p53 and EGFRvIII the data are contradictory. Our aim was to investigate the markers mentioned above regarding progression-free (PFS) and overall survival (OS) to evaluate their viability as independent prognostic markers for our patient collective. Methods: In this retrospective study, we collected data on patients undergoing radiotherapy due to isocitrate dehydrogenase (IDH) wildtype glioblastoma at a single university hospital between 2014 and 2020. Results: Our findings confirm Ki-67 labeling index ≤ 20% as an independent prognostic factor for prolonged PFS as well as MGMT promoter methylation for both prolonged PFS and OS, in consideration of age and Eastern Cooperative Oncology Group (ECOG) status, chemotherapy treatment, and total radiation dose for PFS as well as additionally sex, resection status, and receipt of treatment for progression or recurrence for OS. Additionally, Ki-67 labeling index ≤ 20% showed a significant correlation with prolonged OS in univariate analysis. Modification of the recursive partitioning analysis (RPA) score to include Ki-67 labeling index resulted in a classification with the possible ability to distinguish long-term-survivors from patients with unfavorable prognosis. Conclusion: MGMT promoter methylation and Ki-67 labeling index were independent predictors of survival in our collective. We see further studies pooling patient collectives to reach larger patient numbers concerning Ki-67 labeling index as being warranted.
- 1 August 2021
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 567, 215-221
DYRK3 contributes to differentiation and hypoxic control in neuroblastoma
- 1 August 2021
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 567, 215-221
DYRK3 contributes to differentiation and hypoxic control in neuroblastoma
- Open Access
- 27 December 2018
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 6 (1) , 145
Homozygous TBC1 domain-containing kinase (TBCK) mutation causes a novel lysosomal storage disease – a new type of neuronal ceroid lipofuscinosis (CLN15)?
Homozygous mutation of TBC1 domain-containing kinase (TBCK) is the cause of a very recently defined severe childhood disorder, which is characterized by severe hypotonia, global developmental delay, intellectual disability, epilepsy, characteristic facies and premature death. The link between TBCK loss of function and symptoms in patients with TBCK deficiency disorder (TBCK-DD) remains elusive. Here we demonstrate for the first time the histopathological characteristics of TBCK deficiency consisting of 1) a widespread and massive accumulation of lipofuscin storage material in neurons of the central nervous system without notable neuronal degeneration, 2) storage deposits in few astrocytes, 3) carbohydrate-rich deposits in brain, spleen and liver and 4) vacuolated lymphocytes. Biochemical examinations ruled out more than 20 known lysosomal storage diseases. These investigations strikingly uncover TBCK-DD as a novel type of lysosomal storage disease which is characterized by different storage products rather than one specific type of accumulated material. Due to the clear predominance of intraneuronal lipofuscin storage material and the characteristic clinical presentation we propose to classify this disease as a new subtype of neuronal ceroid lipofuscinosis (CLN15). Our results and previous reports suggest an autophagosomal-lysosomal dysfunction caused by enhanced mTORC1-mediated autophagosome formation and reduced Rab-mediated autophagosome-lysosome fusion, thus disclosing potential novel targets for therapeutic approaches in TBCK-DD.
- 27 December 2018
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 6 (1) , 145
Open AccessHomozygous TBC1 domain-containing kinase (TBCK) mutation causes a novel lysosomal storage disease – a new type of neuronal ceroid lipofuscinosis (CLN15)?
Homozygous mutation of TBC1 domain-containing kinase (TBCK) is the cause of a very recently defined severe childhood disorder, which is characterized by severe hypotonia, global developmental delay, intellectual disability, epilepsy, characteristic facies and premature death. The link between TBCK loss of function and symptoms in patients with TBCK deficiency disorder (TBCK-DD) remains elusive. Here we demonstrate for the first time the histopathological characteristics of TBCK deficiency consisting of 1) a widespread and massive accumulation of lipofuscin storage material in neurons of the central nervous system without notable neuronal degeneration, 2) storage deposits in few astrocytes, 3) carbohydrate-rich deposits in brain, spleen and liver and 4) vacuolated lymphocytes. Biochemical examinations ruled out more than 20 known lysosomal storage diseases. These investigations strikingly uncover TBCK-DD as a novel type of lysosomal storage disease which is characterized by different storage products rather than one specific type of accumulated material. Due to the clear predominance of intraneuronal lipofuscin storage material and the characteristic clinical presentation we propose to classify this disease as a new subtype of neuronal ceroid lipofuscinosis (CLN15). Our results and previous reports suggest an autophagosomal-lysosomal dysfunction caused by enhanced mTORC1-mediated autophagosome formation and reduced Rab-mediated autophagosome-lysosome fusion, thus disclosing potential novel targets for therapeutic approaches in TBCK-DD.